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Abstract
Background: Deletions and mutations in the NSD1 gene
are the major cause of Sotos syndrome. We wanted to
evaluate the genotype-phenotype correlation in patients
suspected of having Sotos syndrome and determine the
best discriminating parameters for the presence of a
NSD1 gene alteration. Methods: Mutation and fluores-
cence in situ hybridization analysis was performed on
blood samples of 59 patients who were clinically scored
into 3 groups. Clinical data were compared between
patients with and without NSD1 alterations. With logistic
regression analysis the best combination of predictive
variables was obtained. Results: In the groups of typical,
dubious and atypical Sotos syndrome, 81, 36 and 0% of
the patients, respectively, showed NSD1 gene altera-
tions. Four deletions were detected. In 23 patients (2 fam-
ilies) 19 mutations were detected (1 splicing defect, 3
non-sense, 7 frameshift and 8 missense mutations). The
best predictive parameters for a NSD1 gene alteration
were frontal bossing, down-slanted palpebral fissures,
pointed chin and overgrowth. Higher incidences of feed-
ing problems and cardiac anomalies were found. The
parameters, delayed development and advanced bone
age, did not differ between the 2 subgroups. Conclu-
sions: In our patients suspected of having Sotos syn-
drome, facial features and overgrowth were highly pre-
dictive of a NSD1 gene aberration, whereas develop-
mental delay and advanced bone age were not.
Copyright © 2004 S. Karger AG, Basel
Introduction
Sotos syndrome, first described in 1964 [1], is an over-
growth syndrome characterized by pre- and postnatal
accelerated growth with advanced bone age, mental retar-
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dation and distinctive facial features including macroce-
phaly, dolichocephaly, frontal bossing with a high hair-
line, a high palate and a prominent jaw [2]. In 2002 Kuro-
taki et al. [3] identified the NSD1 (nuclear receptor Su-
var, 3–9, enhancer of zeste, trithorax domain protein)
gene, and showed that haploinsufficiency of this gene is
the major cause of the syndrome. Deletions mainly in-
volving the NSD1 gene were found in a group of Japanese
patients [3], and in studies in Europe [4–6] heterozygous
intragenic mutations accounted for most of the Sotos syn-
drome phenotype.
In a British study [4], the majority of the mutations
and deletions in the NSD1 gene were found in a group of
patients with classical Sotos syndrome (76% of 37 pa-
tients). In a group of Sotos-like patients (n = 13) with atyp-
ical characteristics, especially concerning the facial fea-
tures, 30% showed a gene alteration in NSD1. Informa-
tion about relations between genotype and clinical charac-
teristics is limited [5–8]. Rio et al. [5] observed that
macrocephaly and facial gestalt were consistent findings
in a group with gene alterations in NSD1, whereas over-
growth and advanced bone age were not. Comparisons
between patients with deletions and patients with muta-
tions showed more severe mental retardation in the 6
patients with deletions. In another study [8] more central
nervous system, cardiovascular and renal anomalies were
found in patients with deletions. In a German study [6],
no deletions were found but in 90% of the patients sus-
pected of having Sotos syndrome a mutation was de-
tected. Facial characteristics, overgrowth, macrocephaly
and developmental delay correlated best with their molec-
ular results.
In this study we aimed at a detailed comparison of clin-
ical data, especially height, head circumference and bone
age data at different ages, between patients with and with-
out a NSD1 gene mutation or deletion. As in other studies
[4–6] we categorized our patients. We used a clinical score
to divide 59 patients, including 3 families, diagnosed as
having or suspected of having Sotos syndrome into three
categories ranging from typical to atypical Sotos syn-
drome. All were investigated for the presence of NSD1
mutations or deletions and we compared their growth pat-
terns and other clinical characteristics. We addressed the
following questions: (1) what are the differences in clinical
and growth characteristics between patients with and
those without NSD1 gene aberrations, and (2) which
parameters have the highest predictive values for detect-
ing an NSD1 gene aberration?
Patients and Methods
Clinical Analysis
This study was conducted with the prior consent of the Medical
Ethical Committee of the Leiden University Medical Center and
consent was given by the patients and/or their parents. Blood sam-
ples were obtained from 59 patients who were diagnosed as or sus-
pected of having Sotos syndrome. Clinical and biochemical data of
31 of the patients were described in a previous study [9] and 28 were
included later. Clinical data of the first 31 patients were studied and
compared with the classical criteria [2] by an expert panel of 4 clini-
cal geneticists (S.G.K., A.v.H., J.J.v.d.S., E.B.; see Acknowledge-
ments) and a pediatric endocrinologist (J.M.W.). Patients were cate-
gorized into 3 groups: typical (group 1) Sotos syndrome; dubious
(group 2), and atypical (group 3) Sotos syndrome. A clinical scoring
system was developed which best reflected the panel’s decisions on
categorization of the patients (table 1) [9]. In short, in this clinical
scoring system, marks were given for facial characteristics, growth,
head circumference, bone age and development. The following facial
characteristics were scored: antimongoloid slant of palpebral fissures;
high palate; prominent jaw; dolichocephaly; frontal bossing, and high
hairline. The maximum score on growth was given when the height
standard deviation score (SDS) [10, 11] was above 2 for all measure-
ments when corrected for target height SDS (gender corrected mid-
parental height). In familial cases no correction for target height was
made. A head circumference measurement above 2 SDS [11] gave a
maximal score. A maximal score on bone age (2 marks) was given if
at least one measurement was above 1.3 SDS (1p90) using the Greu-
lich and Pyle method [12]. A maximal score on development was
given when the measured IQ score was below 90 or developmental
milestones were delayed. An IQ score of 90 corresponds with an SDS
score of approximately –0.7. Patients with 9–11 marks were catego-
rized as having typical Sotos syndrome, patients with 5–8 marks as
dubious, and 1–4 marks as atypical Sotos syndrome. No patient with
Weaver syndrome was included in this study. The 28 patients
included later were categorized by the panel using the scoring system.
Besides the clinical information used for scoring, additional informa-
tion was collected on birth size parameters [13], body mass index
(Quetelet index, weight (kg)/height (m)2) [14], age at eruption of first
teeth, occurrence of neonatal jaundice, feeding problems in the first
year, hypotonia, strabismus, epilepsy, febrile convulsions, pes pla-
nus, scoliosis, cardiac anomalies, and brain anomalies seen on MRI
or CT scan. One patient showed an additional marker chromosome
consisting of the centromere and a small part of the long arm of chro-
mosome 8 (patient 30) [9].
Families
Three families with more than 1 member showing characteristics
of Sotos syndrome were included. The pedigrees are shown in fig-
ure 1.
Family A. The proband (patient 9; fig. 2A) was referred to the
hospital at the age of 4 years with obesity and developmental delay.
At birth and at the age of 4 years height, weight and head circumfer-
ence were above the 97th percentile. Apart from slight facial features
on physical examination, muscular hypotonia with poor coordina-
tion and clumsiness were found. Her sister (patient 38; fig. 2B) was
22 months old at the first visit with height, weight and head circum-
ference above the 97th percentile. More than her sister, she showed
typical facial features of Sotos syndrome. Physical examination
showed muscle hypotonia and clumsiness. The father’s (patient 44)
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Fig. 1. Pedigrees of the 3 familial
cases.
Table 1. Clinical score for categorization of patients diagnosed as having Sotos syndrome
Criteria Marksa
Facial characteristicsb 5 or 6 present
2, 3 or 4 present
0 or 1 present
5
3
0
Growth Height SDS – TH SDS 12 (all measurements before final height) 2
Height SDS – TH SDS X2 (before final height is reached), but in past
measurements 12 2
Height SDS – TH SDS X2 (all measurements before final height) 0
Bone age 1P90 (at least one X-ray) 2
Too old to measure bone age or = P90 1
!P90 0
Head circumference x2 SDS 1
!2 SDS 0
Development IQ !90 or delayed developmental milestones 1
IQ x90 0
TH = Target height.
a Sum 1–4 = Atypical Sotos syndrome; sum 5–8 = dubious Sotos syndrome; sum 9–11 = typical Sotos syndrome.
b Frontal bossing, high hairline, dolichocephaly, prominent jaw, high arched palate, antimongoloid slant of palpe-
bral fissures.
height was 180 cm, his birth length was 57 cm (3.3 SDS). No intelli-
gence test was performed, but he seemed slow and worked as an
unskilled laborer, whereas his brother and sister have completed high
school and work as professionals.
Family B. The proband (patient 41; fig. 2C), the eldest son of this
family, was suspected of having Sotos syndrome because of advanced
bone age and developmental delay. He did not have all the typical
facial characteristics of Sotos syndrome. Later his brother (patient
55) was also suspected because he had a large head circumference
and behavioral problems. His IQ was in the normal range. The moth-
er (patient 48; fig. 2D) was very tall (+2.6 SDS), and showed some
facial characteristics of Sotos syndrome. She had never had learning
difficulties.
Family C (fig. 2E). The proband, a boy (patient 22) who is one of
a set of dizygotic twins born after in vitro fertilization, was suspected
of having Sotos syndrome at the age of 1.5 years; his head circumfer-
ence was +3.5 SD and he showed delayed developmental milestones.
His twin sister appeared normal. His elder sister (patient 28), also
born after in vitro fertilization, was 4 years old at the time and had no
enlarged head circumference, but showed some facial characteristics
of Sotos syndrome. The mother (patient 47) was one of a set of dizy-
gotic twins and childhood pictures showed facial characteristics of
Sotos syndrome. She was very tall in childhood, but final height was
in the normal range, and she had had some speech problems in child-
hood. Her twin sister showed no characteristics of Sotos syndrome.
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Fig. 2. Photographs of familial cases. A Pa-
tient 9 (family A). B Patient 38 (family A).
C Patient 41 (family B). D Patient 48 (family
B). E Patients 22, 28 and 47 (family C).
Genotype-Phenotype in Sotos Syndrome Horm Res 2004;62:197–207 201
Deletion Analysis
Fluorescence in situ hybridization (FISH) was performed as
described previously [15]. Deletion detection was performed by
hybridizing the PAC clone RP1–251c21 [3], visualized in red, simulta-
neously with the control probe RP1–179p12 (5q23.2), visualized in
green. To trace the parental origin of the deletion, a PCR-based micro-
satellite analysis using three markers located within the common de-
leted region (BV005165, BV005168, D5S2111) was carried out.
Mutation Analysis
Blood samples from the probands and their parents were ob-
tained and genomic DNA was isolated from EDTA anticoagulated
blood by a salting-out procedure. The 22 coding exons of the NSD1
gene (exons 2–23) of the index patients were amplified by PCR using
34 primer pairs (a list available on request). PCR products were puri-
fied using the MultiScreen Assay System (Millipore, Billeria, Mass.,
USA) or the Qiagen Qiamp PCR Purification kit (Westburg, Leus-
den, the Netherlands) and directly sequenced on both strands on an
ABI PRISM 3730 DNA Analyzer (Applied Biosystems, Foster City,
Calif., USA) using the BigDye Terminator chemistry according to the
manufacturer’s instructions (Applied Biosystems). Mutations were
considered pathogenic if they were likely to result in premature trun-
cation of the protein. In case a variant was detected with unknown
clinical significance, parental DNA was analyzed for the specific
sequence variation. When the variant was absent in both parents and
the parents had no sign of Sotos syndrome, the variant was consid-
ered pathogenic. To decide whether a variant with unknown clinical
significance was likely to be pathogenic, in case no parental DNA was
available, its position in the NSD1 gene, the corresponding amino
acid change and the absence in other patients or controls were con-
sidered.
Statistical Analysis
Variables were compared between groups using the Student’s t
test or the ¯ 2 test, whichever was appropriate. Logistic regression was
used to find the combination of the most predictive variables for hav-
ing a NSD1 gene alteration, which was translated into an adjusted
clinical score. The discriminating performance of this score was com-
puted. This included constructing a receiver-operating characteris-
tics (ROC) curve with the computed area under the curve (AUC),
positive likelihood ratio, negative likelihood ratio, positive predic-
tive value, and negative predictive value at the optimal cutoff limit.
Repeated measures analysis, using a linear mixed model, was used to
compare bone age SD scores and growth characteristics over time
between the groups. A p value of !0.05 was considered significant.
Results
In table 2 the clinical scoring and presence of a NSD1
gene mutation or deletion are listed for each patient. Per-
centages of NSD1 gene aberrations in groups 1, 2 and 3
were 81, 36 and 0%, respectively.
Deletions
With FISH analysis, we found a deletion in one of the
copies of the NSD1 gene in 4 patients. Two deletions were
of paternal origin (patient 16, DNA of both parents avail-
able, and patient 35, only maternal DNA available) and
one deletion of maternal origin (patient 19, only maternal
DNA available). For patient 4 the DNA of the parents was
not available. Two patients were categorized in group 1
(patients 4 and 16) and in group 2 (patients 19 and 35).
Mutations
The DNA of 55 patients was screened for NSD1 muta-
tions by sequencing. In 23 patients, including 3 families,
19 different mutations were found. The mutations are
listed in table 3 and include a splicing defect, missense
(n = 8), nonsense (n = 3) and frameshift (n = 7) mutations.
In 2 families missense mutations were found and are dis-
cussed below. For the other 6 missense variants, the par-
ental DNA of both parents could be tested and the muta-
tion occurred de novo, therefore these were considered
pathogenic.
Families
Family A. The father and both daughters were carriers
of a missense mutation 5737A1G, N1913D. This muta-
tion is located in a conserved residue of the SAC (SET
associated Cys-rich) domain and was therefore con-
sidered pathogenic. The proband was categorized into
group 1; her sister and father into group 2.
Family B. In the DNA of the mother and eldest son the
missense variant 607G1A,V203I was detected. The other
son did not carry this variant. It was not located in a func-
tional domain, the amino acid change did not lead to a
change in polarity and in exon 2 no previous pathogenic
mutations have been reported. Therefore this missense
variant was considered nonpathogenic. The DNA of the
grandparents was not available. The proband and the
mother were categorized into group 2 and the brother into
group 3.
Family C. In the DNA of the mother, daughter and son
two missense variants were found, 6241T1G, L2081V
and 7576C1T, P2526S, which were both not detected in
the DNA of the mother’s twin sister who showed no clini-
cal characteristics of the syndrome. Nor was either one of
these detected in any of the other patients. The first vari-
ant is located between the SET (su-var 3–9, enhanced-
zeta, trithorax) domain and the PHDIII (plant homeodo-
main) domain, and this variant was not detected in 58
controls. In contrast to the second variant, the amino acid
change does not lead to a change in polarity. We assume
that one of these mutations is pathogenic, but it is unclear
which. The DNA of the grandparents was not available.
All 3 family members were categorized into group 2.
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Table 2. Clinical scores high to low for 59 patients diagnosed as having Sotos syndrome
Patient Sex Age, years Fac 1 2 3 4 5 6 Gr Ba Hc Dev Sum NSD1
Group 1 1 F 4.3 5 + + + + + + 2 2 1 1 11 mut
2 M 7.4 5 – + + + + + 2 2 1 1 11 mut
3 M 17.8 5 + + + + + + 2 2 1 1 11 mut
4 M 20.3 5 + + + – + + 2 2 1 1 11 del
5 F 1.5 5 – + + + + + 1 2 1 1 10 mut
6 M 4.6 5 + + – + + + 1 2 1 1 10 –
7 M 5.8 5 + + + + + + 1 2 1 1 10 –
8 F 18.9 5 + + + + + + 1 2 1 1 10 mut
9A1 F 4.0 3 – + – + – 2 2 1 1 9 mut
10 M 4.5 3 + + + + 2 2 1 1 9 mut
11 F 5.7 5 + + + + + + 1 1 1 1 9 mut
12 M 7.8 5 + – + + + + 2 0 1 1 9 mut
13 M 8.5 5 + + + + – + 0 2 1 1 9 mut
14 M 15.2 5 + + + – + + 1 1 1 1 9 mut
15 M 15.3 3 – + + – – 2 2 1 1 9 –
16 M 25.6 5 + + + + + + 0 2 1 1 9 del
Group 2 17 F 3.3 3 – + + + 2 2 0 1 8 –
18 M 3.5 5 + – + + + + 1 0 1 1 8 mut
19 M 4.2 5 + + + + + + 1 0 1 1 8 del
20 M 7.5 3 + + – + + 1 2 1 1 8 mut
21 F 33.4 3 – – – + + + 1 2 1 1 8 –
22C1 M 2.1 5 + + – + + + 0 0 1 1 7 mut
23 M 3.0 3 – – – – + + 0 2 1 1 7 mut
24 M 3.8 3 + – + – + + 0 2 1 1 7 –
25 M 4.1 3 + – + – + + 1 2 0 1 7 –
26 F 4.3 3 + – – – + 2 2 0 0 7 mut
27 F 4.4 5 + + + + + 0 0 1 1 7 mut
28C2 F 4.5 3 + – + – + + 1 2 0 1 7 mut
29 M 4.9 5 – + + + + + 0 0 1 1 7 –
30 M 5.6 3 – + – + + – 0 2 1 1 7 –
31 F 7.2 3 – + + – + + 0 2 1 1 7 –
32 F 9.2 3 – + – + – – 0 2 1 1 7 –
33 M 20.6 3 + + – – + + 0 2 1 1 7 –
34 M 33.5 3 – + + – + + 1 1 1 1 7 mut
35 M 33.8 3 + + – + + 0 2 1 1 7 del
36 F 0.8 3 – – – + + + 0 2 1 0 6 mut
37 M 1.8 3 – – – + + + 0 2 0 1 6 –
38A2 F 1.8 3 + + – + + 2 0 1 0 6 mut
39 F 4.8 3 – + – + + + 1 0 1 1 6 –
40 F 6.3 0 – – – – – 2 2 1 1 6 –
41B1 M 10.7 3 – + – + – – 0 2 0 1 6 –
42 F 14.0 3 – + + – + + 0 1 1 1 6 –
43 M 36.3 3 – + – – + + 0 1 1 1 6 –
44A3 M 38.0 3 – + – + – 0 1 1 1 6 mut
45 M 6.2 3 – + – – + + 1 0 0 1 5 –
46 F 10.2 0 – – – – + – 1 2 1 1 5 –
47C3 F 36.3 3 – – + – + – 1 1 0 0 5 mut
48B3 F 42.8 3 + + + – – – 1 1 0 0 5 –
49 M 48.4 3 – + + – – – 0 1 0 1 5 –
Group 3 50 M 7.6 3 – – + – + – 0 0 1 0 4 –
51 M 10.1 0 – – – – – – 2 1 0 1 4 –
52 F 11.5 3 – + + – – – 0 1 0 0 4 –
53 M 12.8 0 – + – – – – 2 0 1 0 3 –
54 F 5.7 0 – + – – – – 2 0 0 0 2 –
55B2 M 8.2 0 – + – – – – 1 0 1 0 2 –
56 M 8.6 0 – – – – – – 0 0 1 1 2 –
57 M 8.8 0 – – – – – – 0 0 1 1 2 –
58 M 7.3 0 – – – – – – 0 0 0 1 1 –
59 M 9.6 0 – – – – – – 0 0 0 1 1 –
Fac = Facial characteristics (1 = down-slant palpebral fissures, 2 = high arched palate, 3 = prominent jaw, 4 = dolichocephaly, 5 = frontal bossing, 6 = high
hairline); Gr = growth; Ba = bone age; Hc = head circumference; Dev = development; mut = mutation; del = deletion.
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Genotype-Phenotype Correlation
For all the clinical and growth characteristics men-
tioned below a comparison was made between patients
with deletions and patients with mutations and no signifi-
cant difference was found. For subsequent genotype-phe-
notype correlations we divided all patients in 2 groups,
either having a NSD1 gene aberration or not.
Clinical Score
In the group of patients in which NSD1 deletions or
mutations were found, the total score and the subscores
for facial characteristics and head circumference were sig-
nificantly higher than in the group in which no NSD1
gene abnormalities were found (table 4). The subscores
for growth and bone age were also higher, but the differ-
ence was not significant. The subscore for development
was not different between groups. The percentages of
patients with developmental delay were similar in both
groups. Mean IQ scores for those tested were 75 in the
group with mutations or deletions (n = 11) and 78 for the
other group (n = 17). Bone age SD scores were compared
in a repeated measures analysis and no overall statistical
difference between the groups was detected (p = 0.46).
Also the patterns over time were similar (test for interac-
tion between age and group yields, p = 0.14). In figure 3
the difference between bone age and calendar age is
shown as a function of calendar age.
Predictive Variables for the Presence of a NSD1 Gene
Aberration
With an adjusted score, computed by logistic regres-
sion analysis, we determined the parameters with the
highest predictive value for NSD1 gene alteration. Vari-
ables which showed univariate significance with a p value
of 0.20 or lower were included in a logistic regression
model with a backward selection procedure. The resulting
prognostic score was: –4.71 (1.37) + 1.26 (0.74) ! (down-
slant palpebral fissures) + 1.3 (0.75) ! (pointed chin) +
3.1 (1.18) ! (frontal bossing) + 0.82 (0.49) ! (growth
score). The numbers between brackets are the standard
errors. For simplification, numbers were rounded result-
ing in the following scoring system: Total score = 1!
(down-slant palpebral fissures) + 1! (pointed chin) + 2!
(frontal bossing) + 0.5! (growth score). The score for
growth as mentioned in table 1 would be replaced by 0,
0.5 or 1 mark. This means frontal bossing is the most
Table 3. NSD1 mutations found in 23 patients
Exon Mutation AA Change Name Domain Patient and comment
5 1427T1A L476X nonsense – 1
5 1969insA E675fsX frameshift – 12
5 2809delCGinsT R937X frameshift – 3
5 3531delT F1177fsX1218 frameshift – 8
5 3550insT E1184fsX frameshift – 13 (also found by Douglas)
5 3680T1G L1227X nonsense – 5
7 4108C1T Q1370X nonsense – 34
11 4548–4549delGGinsC E1516fsX frameshift – 2
13 4912delCACA H1638fsX frameshift – 27
14 5129G1A C1710Y missense PHDII 23
16 5435T1A V1812D missense PWWPI 14
18 5737A1G N1913D missense SAC family A
18 5740C1T R1914C missense SAC 20
18 5885T1C I1962T missense SET 26
19 5950C1G R1984G missense SET 11 (5951G1A, R1984Q,
found by Rio)
21 6241T1G L2081V missense (p?) – family C
23 6604T1C C2202R missense – 36
23 7576C1T P2526S missense (p?) – family C
23 7618delT S2540fsX frameshift – 18
intron IVS5+33A1T splicing defect 10
* p? = Pathogenic?, both mutations were detected in one family and it is not known which one is pathogenic.
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important characteristic, followed by the two other facial
characteristics and overgrowth. The total score ranges
from 0 to 5. The AUC of the score from a constructed
ROC curve was 0.88, in comparison with 0.82 for the ini-
tial score. The optimal cutoff limit was a score of 63.5. At
this cutoff limit the positive likelihood ratio was 3.16
(confidence interval (CI) 1.79–5.59) and the positive pre-
dictive value 0.73 (CI 0.60–0.83). The negative likelihood
ratio was 0.15 (CI 0.05–0.46) and the negative predictive
value 0.89 (CI 0.72–0.96).
Fig. 3. Bone age (Greulich and Pyle method) – calendar age in
years.
Table 4. Comparison of the clinical scores and clinical problems between patients with mutations or deletions in the NSD1 gene and those
without
Group with NSD1
mutation or deletion (n = 27)
Group without NSD1
mutation or deletion (n = 32)
p value
Total clinical score (mean) 8.3 5.5 !0.001
Score facial characteristics 0 3 5 0 3 5
0% 44% 56% 31% 69% 9% 0.001
Down-slanted palpebral fissures 67% 19% !0.001
Higharched palate 52% 56% 0.74
Prominentjaw 82% 38% 0.001
Dolichocephaly 56% 34% 0.11
Frontal bossing 96% 50% !0.001
High hair line 85% 44% 0.001
Sum 6 items (mean) 4.4 2.4 !0.001
Score growth 0 1 2 0 1 2
30% 37% 33% 53% 28% 19% 0.07
Score bone age 0 1 2 0 1 2
22% 19% 59% 34% 19% 47% 0.29
Score head circumference 89% 63% !0.05
Score development 85% 81% 0.69
Neonatal jaundice 58% (n = 7) 36% (n = 8) 0.22
Feeding problems 86% (n =12) 35% (n = 7) !0.01
Hypotonia 68% (n= 13) 59% (n = 17) 0.50
Strabismus 40% (n = 8) 42% (n = 11) 0.88
Cardiac anomaly 21% (n = 5) 0% (n = 0) !0.01
Epilepsy 0% (n = 0) 7% (n = 2) 0.22
Febrile convulsions 29% (n = 5) 13% (n = 3) 0.18
Scoliosis 17% (n = 3) 21% (n = 5) 0.74
Pes planus 40% (n = 6) 29% (n = 6) 0.48
Brain anomaly on CT scan 63% (n = 5) 47% (n = 8) 0.48
Otitis 71.5% (n = 10) 70.5% (n = 12) 0.96
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Table 5. Growth characteristics in mean standard deviation scores (SDS) of patients suspected of having Sotos syndrome
NSD1 Birth 0.5 years 1 year 2 years 4 years 10 years Adult
Height SDS
Mut/del
No mut/del
1.90 (n = 23)
1.00 (n = 25)
2.03 (n = 15)
1.49 (n = 20)
2.47 (n = 16)*
1.69 (n = 23)
2.07 (n = 19)
1.81 (n = 23)
2.58 (n = 18)
1.96 (n = 26)
2.19 (n = 5)
1.96 (n = 13)
0.94 (n = 8)
1.16 (n = 8)
Head circumference SDS
Mut/del
No mut/del
1.52 (n = 17)
1.19 (n = 24)
2.16 (n = 15)
1.80 (n = 21)
2.61 (n = 17)
2.04 (n = 22)
2.80 (n = 19)
2.24 (n = 21)
2.72 (n = 19)
2.35 (n = 23)
3.25 (n = 6)
2.88 (n = 12)
2.77 (n = 7)
2.64 (n = 7)
* p ^ 0.05.
Growth Characteristics
Until the age of 10 years height SD scores are higher in
the group with NSD1 gene alteration (table 5). A signifi-
cant difference between the mean SD scores of length was
found at the age of 1 year. Repeated measures analysis
showed that the group with NSD1 gene alterations had a
significantly larger length SDS (estimated difference 0.75;
95% CI 0.22, 1.29). The pattern over time did not differ
significantly between the 2 groups (test for interaction
between time and group, p = 0.86). When a correction was
made for target height SDS, no change in significance was
found, height SDS was higher in the patients with NSD1
gene alterations at all ages. Head circumference SD scores
also tended to be higher, but the difference was not signifi-
cant (estimated difference 0.45; 95% CI –0.025, 0.92; test
for interaction between time and group, p = 0.06). No sig-
nificant difference was found in birth weight SDS, 0.54
(n = 22) in the group with a mutation or deletion and 0.32
(n = 27) in the other group (p = 0.62). Body mass index did
not differ significantly between groups.
Clinical Problems
Information on several clinical problems was com-
pared between both groups (table 4). Significantly higher
incidences were found for feeding problems in the first
year and cardiac anomalies in the group with NSD1 gene
alterations. Cardiac anomalies consisted of persistent
ductus arteriosus, atrial septum defect, mitral insufficien-
cy and coarctation of the aorta. One of these patients (pa-
tient 19) had a NSD1 deletion, and the others a mutation.
Brain anomalies seen on CT scan were large ventricles.
Age at the time of eruption of the first teeth in months was
6.1 (n = 11) for the group with NSD1 mutations or dele-
tions and 6.2 (n = 14) for the group with no gene abnor-
malities (p = 0.88).
Discussion
Our study clearly showed that, using the clinical scor-
ing system, high scores predicted the detection of a NSD1
mutation or deletion in patients suspected of having Sotos
syndrome. Significant differences between patients with
gene alterations of NSD1 and those without were found
for higher length SDS in the former and a higher inci-
dence of the following facial characteristics: antimongo-
loid slant of palpebral fissures; prominent chin; frontal
bossing, and high hairline. Also a higher incidence of feed-
ing problems and cardiac anomalies was found. The most
important parameters for predicting NSD1 mutations or
deletions in this study were frontal bossing, followed by
antimongoloid slant of palpebral fissures, prominent jaw
and overgrowth.
There is quite some variation between the ways of cate-
gorizing the patients in our study and 3 previously pub-
lished studies [4–6]. Although 4 similar criteria were used
in all studies, bone age (11.3 SDS), growth (12 SDS),
head circumference (12 SDS) and dysmorphic facial fea-
tures, development and congenital anomalies were not
consistent criteria. Furthermore, the number of fulfilled
criteria for inclusion in the different studies varied. We
included patients if a diagnosis of Sotos syndrome was
considered which resulted in the inclusion of patients
with only one feature, whereas in other studies patients
had to have more features. Both ways can result in a bias
in the collection of patients. In our study height SDS was
corrected for target height SDS, which was not done in
other studies. NSD1 gene alterations were detected in
81% of our patients in the typical Sotos syndrome group.
This percentage is comparable to the British study which
reported 76% [4]; the French study [5] reported 70%, and
a German study 90% [6]. This high percentage of 90%
could be due to the small size of their study group. Differ-
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ences between the studies could also be due to the number
of fulfilled criteria necessary for inclusion in the typical
Sotos groups.
In the European studies the amount of deletions was
small (n = 3, n = 6 and n = 0) in 75, 39 and 37 patients (4,
15 and 0%) [4–6]. Deletions were also found in Sotos-like
patients: n = 1 [4] and n = 4 [5]. We found 4 deletions
(6%): 2 in patients with typical and 2 in patients with
dubious Sotos syndrome. This low percentage in Euro-
pean countries is in contrast to the high rate of deletions
(67%) observed in a study in Japan [3]. The difference is
thought either to be attributable to patient selection bias
or a population-specific genomic structure [16].
The locations of 2 mutations in our study have been
described before. The frameshift mutation 3550insT,
E1184fsX was detected earlier [4]. In our study a patient
showed a missense mutation located in the SET domain:
5950C1G, R1984G. In another study [5] a patient with a
missense mutation in the same amino acid was described
as 5951G1A, R1984Q.
In accordance with others [17] the majority of the
detected mutations are de novo and apparently there are
no clear hot spots for mutations. Most missense muta-
tions detected in our study are located in one of the func-
tional domains. Three are not located in a functional
domain. For 1 case, parental DNA did not show the muta-
tion, therefore this mutation in exon 23 was considered
pathogenic. The other 2 were found in 1 family (family C)
and located in exons 21 and 23, respectively. It is not yet
clear which of these mutations (6241T1G or 7576C1T) is
the pathogenic one. The DNA of the grandparents was not
available.
Our observation in families A and C indicate that phe-
notypes can differ between patients with the same geno-
type. For example the 2 sisters in family A showed differ-
ent facial characteristics. This suggests that interactions
between NSD1 and other as yet undefined genetic or envi-
ronmental factors may influence the expression of typical
features of Sotos syndrome. We have one observation (pa-
tient 47) of less typical facial features in adulthood than in
childhood.
Facial characteristics were also identified by others [5,
6] as consistent findings in patients with NSD1 gene alter-
ations. In our study frontal bossing, followed by antimon-
goloid slant of palpebral fissures, prominent jaw and a
high hairline were most predictive. A high hairline was
highly associated with frontal bossing and therefore not
found in the score developed by logistic regression analy-
sis. Dolichocephaly and a high arched palate were less
predictive, although for the last feature data were missing
for 9 patients. In our study overgrowth was more extreme
in the group with gene alterations of NSD1. Although
cross-sectional data were used in our study, the over-
growth is seen especially in the first years of life as
described before for a group of patients with suspected
Sotos syndrome [18]. Mean SD scores were above 2 for
ages between 0.5 and 10 years. The number of patients
who have already reached final height is small in our
study. Overgrowth was not a consistent finding in the
French study [5]. Other studies [6, 8] pointed to over-
growth as an important predictor.
Advanced bone age in patients with gene alterations of
NSD1 was not a consistent finding in other studies [5].
The mean bone age of all patients suspected of having
Sotos syndrome was found to be advanced with no differ-
ence between patients with gene alterations of NSD1 and
those without. In our study developmental delay was also
not discriminatory because both groups showed the same
percentage of patients with developmental delay. Both
advanced bone age and delayed development are impor-
tant findings for considering Sotos syndrome, but in the
selected group of patients suspected of having Sotos syn-
drome they were not more extreme than in patients with
mutations or deletions in the NSD1 gene.
Muscular hypotonia (68%) or developmental delay
could play a role in the higher incidence of feeding prob-
lems in the first year. In our study, a higher incidence of
cardiac anomalies was found in the group with NSD1
gene alterations, although it should be noted that the
number of patients was very small. Height SD scores of
these patients where between +0.4 and +3.2 SDS. In con-
trast with a previous study [8] in which cardiac anomalies
were exclusively found in patients with deletions, in our
study anomalies were also found in patients with muta-
tions. Other studies have compared patients carrying mu-
tations with patients carrying deletions and found that
patients with deletions have more severe mental retarda-
tion [4, 8] and less overgrowth. We compared all the
parameters studied between these 2 groups, but could not
find significant differences. However, one should note
that our group of patients with deletions was very small.
Nowadays most patients suspected of Sotos syndrome
will be screened for mutations or deletions in the NSD1
gene. The combination of the parameters with the highest
predictive value for NSD1 gene alterations translated into
a score could assist in deciding for mutation or deletion
screening. No deletions or mutations were detected in our
patients with a score below 2 and all patients with the
maximum score of 5 showed gene alterations of NSD1.
However, this score should be evaluated in a new group of
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patients. Furthermore it should be realized that the study
group is a pre-selected group of patients with one or more
of the clinical characteristics. In some typical Sotos pa-
tients, we did not detect alterations in NSD1. It is possible
that they are carriers of genomic rearrangements in the
NSD1 gene like small deletions and duplications that will
not be detected by direct sequencing and FISH analysis as
performed in our study.
In conclusion, in this study on genotype-phenotype
correlations in patients suspected of Sotos syndrome,
frontal bossing, pointed chin, down-slanted palpebral fis-
sures and overgrowth were the most important predictive
variables for having a gene alteration in one of the copies
of the NSD1 gene. Besides detecting gene alterations in
typical Sotos patients, mutations were also detected in
some patients showing only one or a few characteristics.
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